ATP11 Antibody

What is ATP11A and why is it important in scientific research?

ATP11A functions as a catalytic component of the P4-ATPase flippase complex, which catalyzes ATP hydrolysis coupled to the transport of aminophospholipids (specifically phosphatidylserines and phosphatidylethanolamines) from the outer to the inner leaflet of the plasma membrane . This protein plays a crucial role in maintaining membrane lipid asymmetry with specific functions in muscle cell morphogenesis. In myoblasts, ATP11A mediates phosphatidylserine enrichment at the inner leaflet of plasma membrane, triggering PIEZO1-dependent Ca²⁺ influx and Rho GTPases signal transduction, subsequently leading to the assembly of cortical actomyosin fibers and myotube formation . Research on ATP11A is particularly valuable for understanding fundamental cellular processes involving membrane dynamics and for investigating developmental abnormalities, as evidenced by embryonic lethality in Atp11a-deficient mice .

What experimental applications are ATP11A antibodies suitable for?

Based on validated research protocols, ATP11A antibodies have been successfully employed in several experimental applications:

When designing experiments, researchers should consider that ATP11A antibodies have been tested successfully with human samples, and cross-reactivity with other species should be determined experimentally or predicted based on sequence homology .

How can I validate the specificity of an ATP11A antibody?

Validating antibody specificity is crucial for reliable experimental outcomes. A comprehensive validation approach should include:

• Western blot analysis comparing wild-type and ATP11A-knockout or knockdown samples. For example, researchers have confirmed antibody specificity by demonstrating the presence of an ~130-kDa band in wild-type heart tissue that was absent in Atp11a k/k heart tissue .

• Immunofluorescence comparisons between cells with normal and reduced ATP11A expression to confirm specific labeling patterns.

• Peptide competition assays using the immunizing peptide to block specific antibody binding.

• Cross-reactivity testing against other ATP11 family members (ATP11B, ATP11C) to ensure specificity within the protein family.

• Recombinant protein expression systems to confirm antibody reactivity with the target protein.

For conclusive validation, combining multiple approaches is recommended, particularly when studying tissues with potential maternal contamination as observed in placental samples .

How can ATP11A antibodies be used to study membrane lipid asymmetry?

Investigating membrane lipid asymmetry using ATP11A antibodies requires sophisticated experimental design:

• Co-localization studies: Combine ATP11A immunolabeling with fluorescent lipid probes (Annexin V for PS exposure) to correlate ATP11A expression with lipid distribution across membrane leaflets.

• Flippase activity assays: Use fluorescent-labeled phospholipid analogs to measure internalization rates in cells with varying ATP11A expression levels (detected by antibodies).

• Calcium signaling correlation: Since ATP11A activity in myoblasts triggers PIEZO1-dependent Ca²⁺ influx, researchers can simultaneously monitor ATP11A localization and calcium flux using appropriate indicators .

• Membrane fraction analysis: Combine subcellular fractionation with ATP11A immunoblotting to quantify protein levels in different membrane compartments.

When interpreting results, researchers should consider that ATP11A does not show flippase activity toward phosphatidylcholine (PC), making this an important negative control in experimental designs .

What methodological approaches are recommended for studying ATP11A's role in embryonic development?

Research on ATP11A's developmental functions requires specialized approaches:

• Temporal expression analysis: Use ATP11A antibodies to track protein expression throughout developmental stages, particularly in tissues where defects manifest in knockout models (placenta, heart).

• Tissue-specific knockout comparisons: Compare ATP11A expression in global versus tissue-specific knockouts to understand compensatory mechanisms. For example, while global Atp11a deficiency in mice causes embryonic lethality, cardiomyocyte-specific deletion does not adversely affect development .

• Cross-platform validation: Combine antibody-based protein detection with mRNA analysis. For instance, real-time RT-PCR analysis showed that Atp11c mRNA was present at ~30% of Atp11a mRNA levels in heart tissue, suggesting potential compensatory mechanisms .

• Lineage-specific expression profiling: Use ATP11A antibodies in conjunction with lineage markers to identify cell populations dependent on ATP11A function.

When studying placental development specifically, researchers should examine syncytiotrophoblast formation using dual-immunostaining with ATP11A antibodies and markers such as MCT1 (for SynT-I) and MCT4 (for SynT-II) .

How can I distinguish between different ATP11 family members in my research?

Differentiating between ATP11A, ATP11B, and ATP11C requires careful experimental design:

• Antibody selection: Use antibodies raised against non-conserved regions of each protein. Specifically, antibodies targeting synthetic peptides within unique regions of each protein show higher specificity .

• Expression profiling: Perform comparative analysis across tissues, as each ATP11 family member shows distinct expression patterns. For example, mouse placenta expresses ATP11A but not ATP11C, while both are present in heart tissue at different levels .

• Knockout validation: Use tissue from knockout models as negative controls. Western blotting with a monoclonal antibody against mouse ATP11A has been shown to detect an ~130-kDa band in wild-type heart but not in Atp11a k/k heart, confirming specificity .

• Functional assays: Design experiments that exploit the functional differences between family members, such as their distinct substrate specificities or tissue-specific roles.

A comparative analysis table of ATP11 family members can help guide antibody selection:

What are common challenges when using ATP11A antibodies and how can they be addressed?

Researchers frequently encounter several challenges when working with ATP11A antibodies:

• Non-specific banding: Similar molecular weight proteins may appear as false positives. Solution: Include knockout/knockdown controls and perform peptide competition assays to identify specific bands. For example, researchers have identified a non-specific band with a molecular mass similar to ATP11 protein in chloroplast stroma .

• Maternal contamination in developmental studies: When studying embryonic tissues, maternal ATP11A can confound results. Solution: Use tissue-specific markers and carefully designed crosses (heterozygous mothers) to minimize maternal contribution .

• Variable expression levels: ATP11A expression can vary significantly between tissues, making detection challenging. Solution: Adjust antibody concentration based on expected expression levels. For instance, ATP11A levels in placenta were found to be approximately 10-fold higher than in heart tissue .

• Cross-reactivity with other P4-ATPases: The P4-ATPase family comprises 14 members with structural similarities. Solution: Validate antibody specificity against recombinant proteins and use family member-specific epitopes for immunization .

• Epitope masking due to protein interactions: ATP11A functions in a complex with other proteins. Solution: Test multiple fixation and extraction protocols to ensure epitope accessibility.

How should I design controls for ATP11A antibody experiments?

Robust experimental design requires appropriate controls:

• Negative controls:

  • Isotype control antibodies matched to the ATP11A antibody

  • Knockout or knockdown samples (Atp11a k/k tissue has been effectively used as a negative control)

  • Secondary antibody-only controls to assess non-specific binding

• Positive controls:

  • Tissues known to express high levels of ATP11A (placenta for mouse samples)

  • Overexpression systems with tagged ATP11A (Atp11-HA transgenic lines have been used successfully)

  • Recombinant ATP11A protein for western blotting standard curves

• Specificity controls:

  • Peptide competition assays using the immunizing peptide

  • Comparative analysis with different ATP11A antibodies targeting distinct epitopes

  • Cross-validation with mRNA expression data through RT-PCR

• Processing controls:

  • Loading controls appropriate for the subcellular fraction being studied

  • Multiple fixation protocols to rule out fixation artifacts

  • Time-course experiments to account for potential degradation

What are the optimal protocols for immunoprecipitation of ATP11A and its binding partners?

Successful immunoprecipitation of ATP11A requires specific methodological considerations:

• Lysis buffer optimization:

  • Use mild detergents (0.5-1% NP-40 or CHAPS) to preserve membrane protein integrity

  • Include phosphatase inhibitors to maintain phosphorylation states

  • Add protease inhibitors to prevent degradation during isolation

• Pre-clearing strategy:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Include appropriate serum controls (pre-immune serum has been used effectively)

• Antibody coupling:

  • Direct coupling to CNBr-activated agarose improves specificity and reduces background

  • Alternatively, use magnetic beads coated with protein A/G for cleaner preparations

• Washing conditions:

  • Start with mild washing conditions and increase stringency as needed

  • Include detergent in wash buffers to reduce non-specific membrane protein interactions

• Elution methods:

  • Competitive elution with immunizing peptide maintains protein-protein interactions

  • Acidic glycine elution (pH 2.5-3.0) for stronger antibody-antigen interactions

  • SDS elution for maximum recovery but at the cost of denaturing complexes

These protocols have been successfully applied to immunoprecipitate ATP11 from both mitochondrial preparations and chloroplast stroma .

How can ATP11A antibodies be used to investigate the relationship between ATP11A and disease models?

ATP11A antibodies serve as valuable tools for investigating disease mechanisms:

• Cancer research applications:

  • Quantify ATP11A expression across tumor types and correlate with progression

  • Investigate the relationship between ATP11A expression and drug resistance, particularly with farnesyltransferase inhibitor drugs like lonafarnib

  • Monitor changes in membrane asymmetry as a potential biomarker

• Developmental disorder investigations:

  • Compare ATP11A expression patterns between normal and pathological placental development

  • Assess syncytiotrophoblast formation defects using dual immunolabeling approaches

  • Correlate ATP11A expression with cardiac developmental abnormalities

• Neurodegenerative disease models:

  • Examine phospholipid asymmetry in neuronal membranes and its relationship to neurodegeneration

  • Investigate potential roles in microglia and astrocyte function through co-localization studies

• Immunological disorder research:

  • Study B cell development defects in relation to ATP11A/ATP11C expression patterns

  • Investigate macrophage engulfment mechanisms related to phosphatidylserine exposure

When designing disease-related experiments, researchers should consider tissue-specific expression patterns and potential redundancy with other P4-ATPases, particularly ATP11C .

What approaches can be used to study ATP11A post-translational modifications?

Investigating ATP11A post-translational modifications requires specialized methodologies:

• Phosphorylation analysis:

  • Immunoprecipitate ATP11A using validated antibodies followed by phospho-specific western blotting

  • Combine with mass spectrometry to identify specific phosphorylation sites

  • Use phosphatase treatments as controls to confirm phosphorylation-specific signals

• Ubiquitination and degradation studies:

  • Co-immunoprecipitation with ubiquitin antibodies following ATP11A immunoprecipitation

  • Proteasome inhibitor treatments to assess degradation pathways

  • Cycloheximide chase experiments to determine protein half-life

• Glycosylation assessment:

  • Treat samples with glycosidases followed by western blotting to identify glycosylated forms

  • Use lectin affinity techniques in combination with ATP11A antibodies

• Lipid modifications:

  • Metabolic labeling with fatty acid analogs combined with ATP11A immunoprecipitation

  • Mass spectrometry analysis of immunoprecipitated ATP11A to identify lipid modifications

These approaches can provide insights into the regulation of ATP11A activity and localization in different cellular contexts.

How can I apply design of experiments (DoE) methodology to optimize ATP11A antibody-based assays?

Applying DoE principles can significantly improve experimental outcomes when working with ATP11A antibodies:

• Systematic optimization approach:

  • Define clear objectives (specificity, sensitivity, reproducibility)

  • Identify critical parameters (antibody concentration, incubation time, buffer composition)

  • Create factorial designs to test parameter interactions efficiently

• Factor selection and ranges:

  • Primary antibody concentration (typically 1:100 to 1:5000)

  • Incubation time and temperature

  • Blocking agent type and concentration

  • Sample preparation methods

  • Detection system parameters

• Response measurement:

  • Signal-to-noise ratio

  • Coefficient of variation between replicates

  • Linearity of detection

  • Specific vs. non-specific binding ratio

• Design implementation:

  • Use fractional factorial designs for initial screening

  • Apply response surface methodology for optimization

  • Include center points to assess variability and detect non-linear effects

• Analysis and validation:

  • Create mathematical models to predict optimal conditions

  • Validate optimized conditions experimentally

  • Implement robust protocols based on validated models

The DoE approach requires fewer experiments than traditional one-factor-at-a-time optimization while providing insights into parameter interactions that affect assay performance .

How can ATP11A antibodies be integrated with advanced imaging technologies?

Combining ATP11A antibodies with cutting-edge imaging approaches opens new research possibilities:

• Super-resolution microscopy applications:

  • STORM/PALM imaging to visualize ATP11A nanoscale distribution in membrane microdomains

  • SIM microscopy to examine co-localization with other flippase complex components

  • Lattice light-sheet microscopy for live-cell dynamics of ATP11A in membrane remodeling events

• Live-cell imaging strategies:

  • Antibody fragment-based approaches for live-cell applications

  • Correlation with GFP-tagged ATP11A for validation

  • Single-molecule tracking to analyze diffusion dynamics in the membrane

• Correlative light and electron microscopy (CLEM):

  • Combine immunofluorescence with electron microscopy to precisely locate ATP11A at ultrastructural level

  • Immunogold labeling for transmission electron microscopy

  • Focus ion beam scanning electron microscopy (FIB-SEM) for 3D ultrastructural analysis

• Functional imaging approaches:

  • Combine ATP11A immunolabeling with calcium imaging to study PIEZO1-dependent pathways

  • Correlate with phosphatidylserine sensors to directly visualize flippase activity

  • FRET-based approaches to study protein-protein interactions in situ

These advanced imaging applications require careful optimization of fixation, permeabilization, and immunolabeling protocols to preserve both protein localization and membrane structure.

What are the considerations for using ATP11A antibodies in multiomics research approaches?

Integrating ATP11A antibody-based data with other omics platforms requires specific considerations:

• Proteomics integration:

  • Use ATP11A immunoprecipitation followed by mass spectrometry to identify interaction partners

  • Compare proteome changes in ATP11A-deficient vs. wild-type tissues

  • Correlate ATP11A expression with changes in membrane proteome composition

• Lipidomics correlation:

  • Analyze membrane lipid composition changes in relation to ATP11A expression levels

  • Quantify phosphatidylserine and phosphatidylethanolamine distribution in membrane fractions

  • Compare lipid profiles between ATP11A knockout and wild-type samples

• Transcriptomics connections:

  • Correlate ATP11A protein expression with mRNA levels across tissues

  • Analyze transcriptional changes in response to ATP11A modulation

  • Identify potential compensatory mechanisms (e.g., upregulation of ATP11C)

• Epigenomic considerations:

  • Investigate epigenetic regulation of ATP11A expression

  • Correlate chromatin modifications with tissue-specific expression patterns

• Systems biology approaches:

  • Integrate antibody-based quantification data into pathway models

  • Network analysis of ATP11A interactions and functional relationships

  • Mathematical modeling of membrane asymmetry maintenance

This multiomics integration allows researchers to place ATP11A function in broader biological contexts and identify novel regulatory mechanisms and functional relationships.